Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA appoints Isabel De Paoli as communications head

She will replace Walter Huber, who retires inMarch 2016

Merck KGaA Isabel De PaoliMerck KGaA has picked a new head of group communications to take over from Walter Huber, who is set to retire next March after 18 years in the role.

Isabel De Paoli (pictured) is currently head of group strategy at the German life sciences, health and materials company and will officially step into her new role when Huber's tenure ends.

Until then she will spend her time preparing for her new role and Heiko Schön has taken over from her as head of group strategy at Merck.

In her new role, De Paoli will be responsible for all global communications at Merck.

Karl-Ludwig Kley, chairman of Merck's executive board, said: “Isabel De Paoli brings many years of experience in shaping and implementing strategic topics as well as an international background - capabilities that are becoming ever more important in a rapidly changing communications environment.”

De Paoli joined Merck in August 2006 as business development manager, chemicals, was appointed head of strategic planning oncology in 2009 and in 2012 took on responsibility for group strategy.

Prior to joining Merck she began her career as a consultant, working for The Boston Consulting Group and then moving to private equity firm Permira.

11th August 2015

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics